Nurix Therapeutics (NRIX) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Key clinical program updates

• NX-5948 is advancing toward pivotal trials, with a single-arm study of 100+ patients planned for 2025 and a randomized confirmatory trial to follow closely.

• Accelerated approval pathway is anticipated based on current results, with trial initiation expected this year.

• Duration of response for NX-5948 remains uncalculated as patients continue on therapy, but early data suggest promising efficacy and safety.

• The degrader mechanism allows for lower drug exposure and potentially superior safety compared to BTK inhibitors.

• Regular data updates are expected at EHA and ASH, with enrollment ahead of schedule and strong European investigator participation.

Competitive landscape and strategy

• Focused, nimble approach is seen as an advantage over larger competitors, with increased awareness due to other entrants in the degrader space.

• NX-5948 aims to be best-in-class, with potential to displace both covalent and non-covalent BTK inhibitors.

• Activity in kinase-null mutations and wild-type BTK patients suggests a unique therapeutic angle.

• Earlier line settings are not yet reflected in current share price, indicating potential upside.

Immunology and inflammation (I&I) pipeline

• Stepwise I&I strategy begins with autoimmune hemolytic anemia, leveraging rapid and objective clinical readouts.

• Cohorts in CLL with autoimmune hemolytic anemia are open, with plans to expand into non-oncology and CNS indications like MS.

• BTK degradation is expected to offer superior efficacy and safety in autoimmune diseases by removing both kinase and scaffolding functions.

• Initial focus is on life-threatening conditions before expanding to broader indications.

• More details on autoimmune programs are expected later this year, with phase II/III CLL programs planned.